Developing Accessible Monoclonal Antibodies to Treat COVID-19

An Empowered Patient Podcast

Vu Truong, CEO of Aridis Pharmaceuticals is taking on the challenge of making an inhaled monoclonal antibody to treat COVID-19 to allow for the easier patient access. 

Drawing on their work in infectious diseases and with a number of monoclonal antibodies candidates to treat bacteria infection associated with superbugs and antibiotic resistance, Aridis is finding ways to overcome lack of usage of similar potent antibodies from Regeneron and Eli Lilly to combat the coronavirus.


Podcast Transcript:

  • LinkedIn Basic Black
  • Twitter Basic Black

FC Global Strategies LLC

Tel. +1 646 450 8909



389 Corona Street, Suite 589

Denver CO 80218 USA


© 2021 FC Global Strategies LLC